MX2011011928A - Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos. - Google Patents

Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos.

Info

Publication number
MX2011011928A
MX2011011928A MX2011011928A MX2011011928A MX2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A
Authority
MX
Mexico
Prior art keywords
composition
therapeutic agents
improve absorption
active ingredient
tablet
Prior art date
Application number
MX2011011928A
Other languages
English (en)
Inventor
Guido Schmitz
Eric R First
Ashish B Patel
Stephanie Petaway-Hickson
Hung-Huar Tong
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43062708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2011011928A publication Critical patent/MX2011011928A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un comprimido con un perfil de disolución potenciado para un ingrediente medicinalmente activo, tal como aspirina y procedimientos para fabricar el comprimido. El comprimido comprende una mezcla de cristales del ingrediente medicinalmente activo y un adyuvante de disolución, tal como carbonato o bicarbonato de sodio o calcio que recubre los cristales tras la molienda conjunta. La mezcla se comprime posteriormente para conformar comprimidos que tienen un perfil de disolución potenciado para el ingrediente medicinalmente activo.
MX2011011928A 2009-05-11 2010-05-10 Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos. MX2011011928A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/387,977 US11135188B2 (en) 2009-05-11 2009-05-11 Method and composition to improve absorption of therapeutic agents
PCT/US2010/001375 WO2010132095A1 (en) 2009-05-11 2010-05-10 Method and composition to improve absorption of therapeutic agents

Publications (1)

Publication Number Publication Date
MX2011011928A true MX2011011928A (es) 2011-12-06

Family

ID=43062708

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011928A MX2011011928A (es) 2009-05-11 2010-05-10 Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos.

Country Status (15)

Country Link
US (1) US11135188B2 (es)
EP (1) EP2429502B1 (es)
AR (1) AR076864A1 (es)
BR (1) BRPI1013509A2 (es)
CA (1) CA2761678A1 (es)
CL (1) CL2011002807A1 (es)
CO (1) CO6460753A2 (es)
EA (1) EA201171399A1 (es)
HU (1) HUE043173T2 (es)
MX (1) MX2011011928A (es)
PL (1) PL2429502T3 (es)
PT (1) PT2429502T (es)
SI (1) SI2429502T1 (es)
UY (1) UY32624A (es)
WO (1) WO2010132095A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
EP2953617B1 (en) * 2013-02-06 2019-10-02 Hermes Arzneimittel GmbH Pharmaceutical compositions incorporating low-dose drugs
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
PT3154528T (pt) 2014-06-11 2023-06-22 SpecGx LLC Composições secas por pulverização possuindo diferentes perfis de dissolução e processos para a sua preparação
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11197830B2 (en) * 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
EP4243781A1 (en) * 2020-11-13 2023-09-20 Bayer HealthCare, LLC Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191225486A (en) 1912-11-06 1913-04-24 Herbert Sefton-Jones Manufacture and Production of Improved Pharmaceutical Preparations.
US2293359A (en) 1941-01-08 1942-08-18 Quisling Sverre Acetyl salicylic acid preparation
FI89004C (fi) 1988-02-16 1993-08-10 Pertti J Neuvonen Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat
RU2099058C1 (ru) 1992-06-15 1997-12-20 Институт химии твердого тела и переработки минерального сырья СО РАН Способ получения твердой быстрорастворимой дисперсной системы, содержащей ацетилсалициловую кислоту
US5665388A (en) 1995-11-13 1997-09-09 Health Corporation Method for preparation of an alkaline and aspirin combination compound
EP1007049A1 (en) 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
RU2170582C1 (ru) 2000-02-17 2001-07-20 Институт химии твердого тела и механохимии СО РАН Способ получения быстрорастворимой таблетированной формы ацетилсалициловой кислоты
CA2565941A1 (en) 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
MXPA06015131A (es) * 2004-06-29 2007-03-26 Nycomed Danmark Aps Manufactura de composiciones farmaceuticas con liberacion precipitada de farmacos insolubles en agua y composiciones farmaceuticas obtenidas por medio del proceso de la invencion.
NZ709754A (en) * 2004-10-21 2017-02-24 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
JP2009517346A (ja) 2005-11-28 2009-04-30 イメイジノット ピーティーワイ エルティーディー 治療用化合物の経口送達系
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents

Also Published As

Publication number Publication date
PL2429502T3 (pl) 2019-07-31
PT2429502T (pt) 2019-03-29
CA2761678A1 (en) 2010-11-18
EA201171399A1 (ru) 2012-05-30
EP2429502A1 (en) 2012-03-21
WO2010132095A8 (en) 2011-07-07
HUE043173T2 (hu) 2019-08-28
AR076864A1 (es) 2011-07-13
CO6460753A2 (es) 2012-06-15
UY32624A (es) 2010-12-31
CL2011002807A1 (es) 2012-06-15
EP2429502A4 (en) 2012-10-24
BRPI1013509A2 (pt) 2016-04-05
WO2010132095A1 (en) 2010-11-18
US20100286100A1 (en) 2010-11-11
SI2429502T1 (sl) 2019-05-31
US11135188B2 (en) 2021-10-05
EP2429502B1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
MX2011011928A (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos.
MY147641A (en) Fast release paracetamol tablets
TR201909173T4 (tr) İşlevselleştirilmiş kalsiyum karbonat içeren hızlı parçalanan katı dozaj formundaki formülasyon ve bunun üretim yöntemi.
MX2012003551A (es) Tabletas transformables via oral.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
UA107967C2 (en) Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan
MX2010007083A (es) Combinacion anti-retroviral.
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
EP2515943A4 (en) MICROCRYSTALLINE CELLULOSE AND CALCIUM CARBONATE COMPOSITIONS USEFUL AS RECOMPACTABLE PHARMACEUTICAL EXCIPIENTS
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
TN2012000507A1 (en) Enteric tablet
IN2015DN03921A (es)
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
PE20120647A1 (es) Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular
MX2015012109A (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
PE20061390A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
EP2384745A3 (en) Modified release pharmaceutical compositions of dexlansoprazole
IN2014MN02156A (es)
PH12015500394A1 (en) Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
IN2014CN04119A (es)
IN2012CH03125A (es)
GEP20115310B (en) Medicinal preparation of amisulpride in the solid form and the method of its manufacture